<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Retinitis pigmentosa: Treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Retinitis pigmentosa: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Retinitis pigmentosa: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Seema Garg, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew F Gardiner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Retinitis pigmentosa (RP) comprises a complex group of inherited dystrophies characterized by progressive degeneration and dysfunction of the retina, primarily affecting photoreceptor and pigment epithelial function [<a href="#rid1">1</a>]. The clinical manifestations of RP include night blindness, loss of peripheral vision from progressive loss of photoreceptors, and variably loss of central vision due to cataracts and macular edema.</p><p>Although there is no cure for RP, treatments are available for managing some aspects of its clinical manifestations [<a href="#rid2">2</a>]. New treatments involving gene therapy, transplantation, and implanted electrical devices, are in active development.</p><p>This topic addresses available treatment options as well as review therapeutic strategies that remain experimental. The clinical manifestations and diagnosis of retinitis pigmentosa are discussed separately. (See  <a class="medical medical_review" href="/d/html/6905.html" rel="external">"Retinitis pigmentosa: Clinical presentation and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Vitamin and nutritional supplementation therapy is beneficial only for a limited group of patients with some forms of retinitis pigmentosa (RP). Several new treatments are on the horizon to slow or possibly even reverse the retinal degeneration caused by photoreceptor loss.</p><p class="headingAnchor" id="H3"><span class="h2">Vitamin and nutritional supplementation</span><span class="headingEndMark"> — </span>A role for vitamin therapy in RP was originally suggested by an observational study in which patients with RP who were taking vitamins A and E appeared to have slower decline in electroretinography (ERG) measurements than those not taking vitamin supplements [<a href="#rid3">3</a>].</p><p>Dietary modification is the definitive therapy for three rare forms of retinitis pigmentosa:</p><p class="bulletIndent1"><span class="glyph">●</span>Abetalipoproteinemia (Bassen-Kornzweig syndrome) – Abetalipoproteinemia is a genetic disorder that causes defective intestinal absorption of lipids, including fat soluble vitamins. Ophthalmologic and neurologic manifestations of abetalipoproteinemia include RP, peripheral neuropathy, ataxia, and, in up to one-third of patients, intellectual and developmental disabilities. Treatment with fat soluble vitamins (E, A, and K) can modify manifestations of the disease. In early stages of disease, <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> and E supplementation may restore retinal function, improving dark adaptation and reversing ERG abnormalities [<a href="#rid4">4-6</a>]. (See  <a class="medical medical_review" href="/d/html/14122.html" rel="external">"Neuroacanthocytosis", section on 'Abetalipoproteinemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Phytanic acid oxidase deficiency (Refsum disease) – Refsum disease is the result of a genetic abnormality in which the enzyme that breaks down phytanic acid is absent. Patients develop RP, cerebellar ataxia, and peripheral polyneuropathy. Severely reducing intake of foods containing phytanic acid, such as dairy products, certain types of meat, and seafood, can slow or stop progression of the disease. (See  <a class="medical medical_review" href="/d/html/6226.html" rel="external">"Neuropathies associated with hereditary disorders", section on 'Refsum disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alpha-tocopherol transport protein deficiency (ataxia with <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> deficiency) – Alpha-tocopherol transport protein deficiency is a hereditary syndrome with RP, ataxia, and vitamin E deficiency. Treatment with vitamin E may halt progression. (See  <a class="medical medical_review" href="/d/html/6234.html" rel="external">"Overview of the hereditary ataxias", section on 'Treatable diseases'</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h3">Vitamin A</span><span class="headingEndMark"> — </span>The role for <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> in the treatment for RP, outside of its well-established indication in patients with abetalipoproteinemia, remains controversial. It is unclear if small potential benefits of vitamin A supplementation outweigh the potential risks. Therefore, we do not recommend high-dose vitamin A for patients with RP.</p><p>In a randomized controlled trial, 601 patients aged 18 to 49 years with RP (including autosomal dominant, autosomal recessive, X-linked non-syndromic and Usher syndrome) were randomly assigned to one of four treatment groups: <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> (15,000 international units/day); <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> (400 international units/day); both vitamin A and E at these doses; or trace amounts of vitamin A and E [<a href="#rid7">7</a>]. Cone ERG amplitudes were measured. At four- to six-year follow-up, patients taking supplemental vitamin A had a slightly lower rate of decline of ERG amplitudes. Results suggested that vitamin E had a negative impact, accelerating the decline of ERG amplitudes in a subset of patients with the highest initial cone ERG results. No significant effect on visual field or visual acuity was noted for either vitamin supplement. There are several limitations in drawing conclusions about the beneficial effects of vitamin A. Positive response to treatment was seen only on the ERG, and no effect was seen on clinically relevant measures of visual function.</p><p>There is a theoretical risk of toxicity from long-term high-dose <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a>. The toxic effects of high-dose vitamin A include hepatomegaly, bone changes such as osteoporosis, elevated blood lipid levels, increased intracranial pressure, and teratogenicity. Although the daily intake of the dose of vitamin A palmitate suggested as treatment for RP (15,000 international units, equivalent to three times the daily allowance) was not shown to be harmful in adults in this study, there are no well-controlled studies on the effect of vitamin A at this dose when taken longer term, such as over decades. (See  <a class="medical medical_review" href="/d/html/2571.html" rel="external">"Overview of vitamin A"</a>.)</p><p>While we do not recommend <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> supplementation for RP, we do suggest that adults with early to middle stages of RP avoid <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> supplements. Patients who have been advised to take vitamin A should have annual fasting vitamin A levels and liver function tests; older patients should be monitored for osteoporosis. High-dose vitamin A supplementation is contraindicated during pregnancy or for those planning to become pregnant, due to teratogenicity.</p><p class="headingAnchor" id="H5"><span class="h3">Marine omega-3 fatty acids</span><span class="headingEndMark"> — </span>Docosahexaenoic acid (DHA), an omega-3 fatty acid found naturally in fish, is a major structural lipid of retinal photoreceptor outer segment membranes [<a href="#rid8">8</a>] and may be involved in rhodopsin regeneration [<a href="#rid9">9</a>]. The long-term effectiveness of DHA on the progression of RP is uncertain. We suggest that patients with RP consume a diet high in omega-3 fatty acids, but we do not suggest that patients take supplemental DHA. </p><p>Although observational studies and subgroup analyses from trial have shown possible benefit of a diet high in omega-3 fatty acids [<a href="#rid10">10-13</a>], no benefit of DHA supplementation was demonstrated in randomized trials:</p><p class="bulletIndent1"><span class="glyph">●</span>A 2013 systematic review involving three randomized trials (one of <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> alone, one of DHA alone, and one comparing DHA plus vitamin A with vitamin A alone) found no effect on the progression of visual field or visual acuity loss, although an effect on ERG amplitudes was demonstrated in some subgroups [<a href="#rid14">14</a>]. A subsequent randomized trial in patients with X-linked RP found that long-term DHA supplementation did not slow loss of cone or rod ERG [<a href="#rid15">15</a>].</p><p></p><p class="headingAnchor" id="H1712230969"><span class="h2">Gene therapy</span><span class="headingEndMark"> — </span>Remarkable progress has been made in the identification of the genes involved in RP and in gene therapy targeting the <em>RPE65</em> gene. </p><p>Mutations in the <em>RPE65</em> gene are one of the causes of RP and Leber congenital amaurosis (LCA), a form of RP present at birth [<a href="#rid16">16</a>]. This gene encodes for a protein involved in the visual cycle, which converts light entering the eye into electrical signals transmitted to the brain. Mutations lead to reduced or absent levels of <em>RPE65</em> activity, with resultant blocking of the visual cycle and impaired vision. </p><p>In cases such as this, where a genetic defect leads to the loss of an encoded protein, gene-replacement therapy can provide a healthy copy of the defective gene, thus allowing the cell to produce the protein. However, timing of gene replacement in the progression of RP is critical, as adequate numbers of viable photoreceptor cells must still be present to produce enough of the missing protein to restore visual function. This is because mutations in retinitis pigmentosa cause the death of rod photoreceptors through apoptosis. In late stages of the condition when most of the rods have been eliminated, cones secondarily slowly degenerate due to progressive oxidative damage [<a href="#rid17">17</a>].</p><p>In 2017, the US Food and Drug Administration (FDA) approved voretigene neparvovec-rzyl (Luxturna), the first directly administered gene therapy that targets <em>RPE65</em>. Voretigene neparvovec-rzyl uses an adeno-associated virus using recombinant DNA techniques and is delivered by a single subretinal injection by a retina specialist. The retinal cells then produce the protein that converts light to an electrical signal in the retina [<a href="#rid18">18</a>].</p><p>This treatment is approved for patients with biallelic (having both a paternal and a maternal mutation) <em>RPE65</em> mutation-associated retinal dystrophy (chronic, bilateral, and progressive disorders of visual function, including RP). This condition affects approximately 1000 to 2000 patients in the United States and is associated with progressive vision loss. This loss of vision can begin as early as the first few months of life (LCA), or during childhood or adolescence, and ultimately progresses to complete blindness. </p><p>Voretigene neparvovec-rzyl represents a significant therapeutic advance which may provide improvement in vision and prevent further deterioration. However, cautious optimism is necessary, as the drug is not expected to restore normal vision, and only about half of treated patients had minimally meaningful improvement in short-term studies [<a href="#rid19">19</a>]. Long-term clinical evidence is pending. </p><p>In the United Kingdom, the National Institute for Health and Care Excellence (NICE) has recommended voretigene neparvovec-rzyl for eligible patients who have enough viable retinal cells. In England, an estimated 86 people will be eligible for treatment [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H4079305623"><span class="h2">Experimental therapies</span></p><p class="headingAnchor" id="H8"><span class="h3">Retinal cell transplantation</span><span class="headingEndMark"> — </span>The potential for transplanted retinas, retinal sheets, and clumps of retinal neurons to restore vision in mice and humans with RP has been under investigation since the 1980s. Until recently, transplanted tissue or cells have not developed synaptic connections with host cells and thus have not had functional impact [<a href="#rid21">21,22</a>].</p><p>The potential for transplantation of fetal retinal pigment epithelium to rescue abnormal photoreceptors in RP is being investigated. After fetal retinal implantation into six patients with RP, slight improvement in visual acuity was seen in three patients (one patient with bilateral improvement including the eye that did not receive the transplant) although the extent of improvement was not clinically significant [<a href="#rid23">23</a>]. Integration of donor cells into the host retina is dependent upon the stage of cell differentiation at the time of donor harvest [<a href="#rid24">24</a>]. Successful integration of committed fetal progenitor cells that developed into functional rod photoreceptors was demonstrated in a mouse model of RP [<a href="#rid24">24</a>]. Transplanted cells did not integrate into the retina in mice with more active disease and more rapid retinal degeneration.</p><p>Regulatory and ethical issues with use of human fetal retinal cells has led to exploration of human embryonic stem cells that might be induced to differentiate into photoreceptor progenitor cells [<a href="#rid25">25</a>]. Such stem cells may also produce factors that enhance survival of host photoreceptors, as demonstrated in mouse models [<a href="#rid26">26,27</a>]. In addition, mouse embryonic stem cells can be used to create a complex three-dimensional array of retinal cells [<a href="#rid28">28</a>].</p><p>A human clinical trial, the Safety Study in Retinal Transplantation for Retinitis Pigmentosa, has completed enrollment [<a href="#rid29">29</a>]. Its long-term goal is to determine if transplantation can prevent blindness or restore eyesight in patients with RP.</p><p class="headingAnchor" id="H9"><span class="h3">Retinal prosthesis devices</span><span class="headingEndMark"> — </span>Devices are being tested that transduce light into electrical signals and transmit this information directly to the inner retina (bypassing the diseased outer retina of RP), optic nerve, or occipital visual cortex. Patients involved in studies of these devices have reported seeing flashes of light and have been able to sense motion, locate large objects, and recognize large letters [<a href="#rid30">30-32</a>]. There are multiple retinal prostheses in clinical trials.</p><p>One retinal prosthesis system (Argus II) converts video images captured from a very small camera housed in the patient’s glasses into a series of small electrical impulses that are wirelessly transmitted to an array of 60 electrodes on the retina [<a href="#rid33">33</a>]. The Argus II was the first artificial retina to receive widespread commercial approval. Second Sight has discontinued new implants of the Argus II system. Vision restoration is theoretically correlated with the number of electrodes. Newer generations of prostheses have increasingly more electrodes, with one in the development phase with over 1000 electrodes [<a href="#rid34">34</a>]. Retinal prostheses have the potential to enhance the quality of life of RP patients by aiding in object recognition, mobility, and independent living.</p><p class="headingAnchor" id="H10"><span class="h1">OTHER INTERVENTIONS</span></p><p class="headingAnchor" id="H11"><span class="h2">Treatment of macular edema</span><span class="headingEndMark"> — </span>Cystoid macular edema can reduce central vision in later stages of retinitis pigmentosa (RP). The most successful treatment thus far is the oral carbonic anhydrase inhibitor <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a>. Acetazolamide increases fluid absorption across the retinal pigment epithelium. In the absence of macular edema, carbonic anhydrase inhibitors do not improve vision or alter the course of electroretinography (ERG) degradation in patients with RP [<a href="#rid35">35</a>].</p><p>In a small crossover trial, 10 of 12 patients with RP and chronic macular edema demonstrated objective and subjective improvement in visual acuity when treated with <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> 500 mg/day [<a href="#rid36">36</a>]. Side effects include peripheral paresthesias, loss of appetite, fatigue, renal stones, and anemia. <a class="drug drug_general" data-topicid="9625" href="/d/drug information/9625.html" rel="external">Methazolamide</a> has fewer side effects but may be less effective [<a href="#rid37">37</a>]. Rebound edema has been reported due to tachyphylaxis to oral carbonic anhydrases [<a href="#rid38">38,39</a>].</p><p><a class="drug drug_general" data-topicid="9386" href="/d/drug information/9386.html" rel="external">Dorzolamide</a>, a topical carbonic anhydrase inhibitor, may be effective for patients who cannot tolerate the systemic effects of oral carbonic anhydrases [<a href="#rid40">40</a>]. In a retrospective cohort study of 32 patients with cystoid macular edema from RP and Usher syndrome who received dorzolamide, 10 patients (31 percent) had improved visual acuity by ≥7 letters [<a href="#rid41">41</a>].</p><p>Case reports of the use of intravitreal <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> in patients with RP and macular edema describe a limited and transient response [<a href="#rid42">42,43</a>]. Large randomized trials have not been conducted.</p><p class="headingAnchor" id="H12"><span class="h2">Cataract extraction</span><span class="headingEndMark"> — </span>Posterior subcapsular cataracts develop in 35 to 51 percent of adult patients with RP [<a href="#rid44">44-46</a>]. Central vision may improve with cataract extraction. However, patients must be counseled that there will be no improvement in their visual field and no impact on progression of disease.</p><p class="headingAnchor" id="H13"><span class="h2">Light restriction</span><span class="headingEndMark"> — </span>Although reduced light exposure decreased the rate of photoreceptor loss in two animal models of RP [<a href="#rid47">47,48</a>], there are no data in humans to support advising patients to limit their exposure to light. Two case studies, involving patients with RP who had restricted light exposure to one eye but not the other, found no difference in ERG results or ophthalmoscopic appearance between the eyes [<a href="#rid49">49,50</a>].</p><p class="headingAnchor" id="H100085446"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83035.html" rel="external">"Patient education: Retinitis pigmentosa (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>There is no cure for the photoreceptor loss or retinal epithelial damage associated with simple retinitis pigmentosa (RP). Some rare forms of RP, associated with multiorgan involvement, are due to specific nutritional deficiencies and may respond to dietary modification or vitamin supplementation. (See <a class="local">'Vitamin and nutritional supplementation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-dose <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> supplementation may slow the rate of decline of the amplitude of the cone photoreceptor electroretinography (ERG) response but has not been shown to slow loss of vision. Except for patients with abetalipoproteinemia, we suggest <strong>not</strong> treating patients with high-dose vitamin A (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Except for patients with rare syndromes of RP related to <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> deficiency, we suggest patients with RP <strong>not</strong> take supplemental vitamin E (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Vitamin A'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The long-term effectiveness of docosahexaenoic acid (DHA), an omega-3 fatty acid, on progression of RP is uncertain. No benefit of DHA supplementation was demonstrated in randomized trials, although observational studies have shown possible benefit of a diet high in omega-3 fatty acids. Until results are available from additional trials, we suggest that patients with RP consume a diet high in omega-3 fatty acids, but we suggest that patients <strong>not</strong> take supplemental DHA (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Marine omega-3 fatty acids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New or experimental approaches to treatment for RP include gene therapy, transplantation of fetal retinal cells or stem cells, and electronic retinal prostheses. (See <a class="local">'Gene therapy'</a> above and <a class="local">'Experimental therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We recommend that patients with macular edema and RP be treated with an oral carbonic anhydrase inhibitor (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>) (see <a class="local">'Treatment of macular edema'</a> above). A topical carbonic anhydrase inhibitor is an alternative in patients who do not tolerate the oral formulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with RP and posterior cataracts will likely benefit from cataract extraction. There is no evidence that reduced light exposure provides benefit for RP patients. (See <a class="local">'Other interventions'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Retinitis pigmentosa. A symposium on terminology and methods of examination. Ophthalmology 1983; 90:126.</a></li><li><a class="nounderline abstract_t">Jacobson SG, Cideciyan AV. Treatment possibilities for retinitis pigmentosa. N Engl J Med 2010; 363:1669.</a></li><li><a class="nounderline abstract_t">Berson EL. Retinitis pigmentosa. The Friedenwald Lecture. Invest Ophthalmol Vis Sci 1993; 34:1659.</a></li><li><a class="nounderline abstract_t">Gouras P, Carr RE, Gunkel RD. Retinitis pigmentosa in abetalipoproteinemia: Effects of vitamin A. Invest Ophthalmol 1971; 10:784.</a></li><li><a class="nounderline abstract_t">Berson EL. Nutrition and retinal degenerations. Int Ophthalmol Clin 2000; 40:93.</a></li><li><a class="nounderline abstract_t">Bieri JG, Hoeg JM, Schaefer EJ, et al. Vitamin A and vitamin E replacement in abetalipoproteinemia. Ann Intern Med 1984; 100:238.</a></li><li><a class="nounderline abstract_t">Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 1993; 111:761.</a></li><li><a class="nounderline abstract_t">Fliesler SJ, Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res 1983; 22:79.</a></li><li><a class="nounderline abstract_t">Chen Y, Houghton LA, Brenna JT, Noy N. Docosahexaenoic acid modulates the interactions of the interphotoreceptor retinoid-binding protein with 11-cis-retinal. J Biol Chem 1996; 271:20507.</a></li><li><a class="nounderline abstract_t">Berson EL, Rosner B, Sandberg MA, et al. ω-3 intake and visual acuity in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol 2012; 130:707.</a></li><li><a class="nounderline abstract_t">Hodge WG, Barnes D, Schachter HM, et al. The evidence for efficacy of omega-3 fatty acids in preventing or slowing the progression of retinitis pigmentosa: a systematic review. Can J Ophthalmol 2006; 41:481.</a></li><li><a class="nounderline abstract_t">Hoffman DR, Locke KG, Wheaton DH, et al. A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa. Am J Ophthalmol 2004; 137:704.</a></li><li><a class="nounderline abstract_t">Berson EL, Rosner B, Sandberg MA, et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol 2004; 122:1306.</a></li><li><a class="nounderline abstract_t">Rayapudi S, Schwartz SG, Wang X, Chavis P. Vitamin A and fish oils for retinitis pigmentosa. Cochrane Database Syst Rev 2013; :CD008428.</a></li><li><a class="nounderline abstract_t">Hoffman DR, Hughbanks-Wheaton DK, Pearson NS, et al. Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial. JAMA Ophthalmol 2014; 132:866.</a></li><li><a class="nounderline abstract_t">Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28:92.</a></li><li><a class="nounderline abstract_t">Campochiaro PA, Mir TA. The mechanism of cone cell death in Retinitis Pigmentosa. Prog Retin Eye Res 2018; 62:24.</a></li><li><a class="nounderline abstract_t">Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 2017; 390:849.</a></li><li><a class="nounderline abstract_t">Darrow JJ. Luxturna: FDA documents reveal the value of a costly gene therapy. Drug Discov Today 2019; 24:949.</a></li><li class="breakAll">National Institute for Health and Care Excellence. Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations. 2019. https://www.nice.org.uk/guidance/hst11 (Accessed on December 09, 2019).</li><li><a class="nounderline abstract_t">Bennett J. Retinal progenitor cells--timing is everything. N Engl J Med 2007; 356:1577.</a></li><li><a class="nounderline abstract_t">Berger AS, Tezel TH, Del Priore LV, Kaplan HJ. Photoreceptor transplantation in retinitis pigmentosa: short-term follow-up. Ophthalmology 2003; 110:383.</a></li><li><a class="nounderline abstract_t">Radtke ND, Aramant RB, Petry HM, et al. Vision improvement in retinal degeneration patients by implantation of retina together with retinal pigment epithelium. Am J Ophthalmol 2008; 146:172.</a></li><li><a class="nounderline abstract_t">MacLaren RE, Pearson RA, MacNeil A, et al. Retinal repair by transplantation of photoreceptor precursors. Nature 2006; 444:203.</a></li><li><a class="nounderline abstract_t">Lamba DA, Karl MO, Ware CB, Reh TA. Efficient generation of retinal progenitor cells from human embryonic stem cells. Proc Natl Acad Sci U S A 2006; 103:12769.</a></li><li><a class="nounderline abstract_t">Meyer JS, Katz ML, Maruniak JA, Kirk MD. Embryonic stem cell-derived neural progenitors incorporate into degenerating retina and enhance survival of host photoreceptors. Stem Cells 2006; 24:274.</a></li><li><a class="nounderline abstract_t">Smith LE. Bone marrow-derived stem cells preserve cone vision in retinitis pigmentosa. J Clin Invest 2004; 114:755.</a></li><li><a class="nounderline abstract_t">Eiraku M, Takata N, Ishibashi H, et al. Self-organizing optic-cup morphogenesis in three-dimensional culture. Nature 2011; 472:51.</a></li><li class="breakAll">http://clinicaltrials.gov/ct2/show/NCT00345917 (Accessed on August 25, 2014).</li><li><a class="nounderline abstract_t">Chuang AT, Margo CE, Greenberg PB. Retinal implants: a systematic review. Br J Ophthalmol 2014; 98:852.</a></li><li><a class="nounderline abstract_t">Luo YH, da Cruz L. A review and update on the current status of retinal prostheses (bionic eye). Br Med Bull 2014; 109:31.</a></li><li><a class="nounderline abstract_t">Dorn JD, Ahuja AK, Caspi A, et al. The Detection of Motion by Blind Subjects With the Epiretinal 60-Electrode (Argus II) Retinal Prosthesis. JAMA Ophthalmol 2013; 131:183.</a></li><li><a class="nounderline abstract_t">Ahuja AK, Dorn JD, Caspi A, et al. Blind subjects implanted with the Argus II retinal prosthesis are able to improve performance in a spatial-motor task. Br J Ophthalmol 2011; 95:539.</a></li><li><a class="nounderline abstract_t">Chader GJ, Weiland J, Humayun MS. Artificial vision: needs, functioning, and testing of a retinal electronic prosthesis. Prog Brain Res 2009; 175:317.</a></li><li><a class="nounderline abstract_t">Greenstein VC, Holopigian K, Siderides E, et al. The effects of acetazolamide on visual function in retinitis pigmentosa. Invest Ophthalmol Vis Sci 1993; 34:269.</a></li><li><a class="nounderline abstract_t">Fishman GA, Gilbert LD, Fiscella RG, et al. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol 1989; 107:1445.</a></li><li><a class="nounderline abstract_t">Fishman GA, Gilbert LD, Anderson RJ, et al. Effect of methazolamide on chronic macular edema in patients with retinitis pigmentosa. Ophthalmology 1994; 101:687.</a></li><li><a class="nounderline abstract_t">Fishman GA, Glenn AM, Gilbert LD. Rebound of macular edema with continued use of methazolamide in patients with retinitis pigmentosa. Arch Ophthalmol 1993; 111:1640.</a></li><li><a class="nounderline abstract_t">Apushkin MA, Fishman GA, Grover S, Janowicz MJ. Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa. Retina 2007; 27:1112.</a></li><li><a class="nounderline abstract_t">Fishman GA, Apushkin MA. Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol 2007; 91:743.</a></li><li><a class="nounderline abstract_t">Genead MA, Fishman GA. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome. Arch Ophthalmol 2010; 128:1146.</a></li><li><a class="nounderline abstract_t">Minnella AM, Falsini B, Bamonte G, et al. Optical coherence tomography and focal electroretinogram evaluation of cystoid macular edema secondary to retinitis pigmentosa treated with intravitreal triamcinolone: case report. Eur J Ophthalmol 2006; 16:883.</a></li><li><a class="nounderline abstract_t">Scorolli L, Morara M, Meduri A, et al. Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone. Arch Ophthalmol 2007; 125:759.</a></li><li><a class="nounderline abstract_t">Heckenlively J. The frequency of posterior subcapsular cataract in the hereditary retinal degenerations. Am J Ophthalmol 1982; 93:733.</a></li><li><a class="nounderline abstract_t">Bastek JV, Heckenlively JR, Straatsma BR. Cataract surgery in retinitis pigmentosa patients. Ophthalmology 1982; 89:880.</a></li><li><a class="nounderline abstract_t">Fishman GA, Anderson RJ, Lourenco P. Prevalence of posterior subcapsular lens opacities in patients with retinitis pigmentosa. Br J Ophthalmol 1985; 69:263.</a></li><li><a class="nounderline abstract_t">Naash ML, Peachey NS, Li ZY, et al. Light-induced acceleration of photoreceptor degeneration in transgenic mice expressing mutant rhodopsin. Invest Ophthalmol Vis Sci 1996; 37:775.</a></li><li><a class="nounderline abstract_t">Cideciyan AV, Jacobson SG, Aleman TS, et al. In vivo dynamics of retinal injury and repair in the rhodopsin mutant dog model of human retinitis pigmentosa. Proc Natl Acad Sci U S A 2005; 102:5233.</a></li><li><a class="nounderline abstract_t">Berson EL. Light deprivation and retinitis pigmentosa. Vision Res 1980; 20:1179.</a></li><li><a class="nounderline abstract_t">Miyake Y, Sugita S, Horiguchi M, Yagasaki K. Light deprivation and retinitis pigmentosa. Am J Ophthalmol 1990; 110:305.</a></li></ol></div><div id="topicVersionRevision">Topic 6911 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6856249" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Retinitis pigmentosa. A symposium on terminology and methods of examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20961252" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment possibilities for retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8473105" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Retinitis pigmentosa. The Friedenwald Lecture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5124019" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Retinitis pigmentosa in abetalipoproteinemia: Effects of vitamin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11064860" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Nutrition and retinal degenerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6691669" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Vitamin A and vitamin E replacement in abetalipoproteinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8512476" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6348799" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chemistry and metabolism of lipids in the vertebrate retina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8702792" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Docosahexaenoic acid modulates the interactions of the interphotoreceptor retinoid-binding protein with 11-cis-retinal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22332205" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ω-3 intake and visual acuity in patients with retinitis pigmentosa receiving vitamin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16883366" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The evidence for efficacy of omega-3 fatty acids in preventing or slowing the progression of retinitis pigmentosa: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15059710" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15364709" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24357340" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Vitamin A and fish oils for retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24805262" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11326284" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Gene therapy restores vision in a canine model of childhood blindness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28962928" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The mechanism of cone cell death in Retinitis Pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28712537" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30711576" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Luxturna: FDA documents reveal the value of a costly gene therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30711576" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Luxturna: FDA documents reveal the value of a costly gene therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17429090" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Retinal progenitor cells--timing is everything.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12578785" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Photoreceptor transplantation in retinitis pigmentosa: short-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18547537" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Vision improvement in retinal degeneration patients by implantation of retina together with retinal pigment epithelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17093405" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Retinal repair by transplantation of photoreceptor precursors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908856" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficient generation of retinal progenitor cells from human embryonic stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16123383" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Embryonic stem cell-derived neural progenitors incorporate into degenerating retina and enhance survival of host photoreceptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15372096" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Bone marrow-derived stem cells preserve cone vision in retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21475194" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Self-organizing optic-cup morphogenesis in three-dimensional culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21475194" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Self-organizing optic-cup morphogenesis in three-dimensional culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24403565" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Retinal implants: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24526779" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A review and update on the current status of retinal prostheses (bionic eye).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23544203" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The Detection of Motion by Blind Subjects With the Epiretinal 60-Electrode (Argus II) Retinal Prosthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20881025" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Blind subjects implanted with the Argus II retinal prosthesis are able to improve performance in a spatial-motor task.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19660665" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Artificial vision: needs, functioning, and testing of a retinal electronic prosthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8425835" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The effects of acetazolamide on visual function in retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2803090" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8152764" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of methazolamide on chronic macular edema in patients with retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8155034" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Rebound of macular edema with continued use of methazolamide in patients with retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18040255" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17215269" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837798" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17191201" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Optical coherence tomography and focal electroretinogram evaluation of cystoid macular edema secondary to retinitis pigmentosa treated with intravitreal triamcinolone: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17562986" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7091261" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The frequency of posterior subcapsular cataract in the hereditary retinal degenerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7133635" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cataract surgery in retinitis pigmentosa patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3994942" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prevalence of posterior subcapsular lens opacities in patients with retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8603862" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Light-induced acceleration of photoreceptor degeneration in transgenic mice expressing mutant rhodopsin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15784735" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : In vivo dynamics of retinal injury and repair in the rhodopsin mutant dog model of human retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7269274" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Light deprivation and retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2396657" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Light deprivation and retinitis pigmentosa.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
